Online inquiry

IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9527MR)

This product GTTS-WQ9527MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FOLH1 gene. The antibody can be applied in Prostate Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2346
UniProt ID Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9527MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1470MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ1859MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ5238MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ839MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ6810MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ4851MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ6524MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ4872MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BTCT4465A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW